Galapagos reports Phase Ib data for GLPG1972 in OA
Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks were well tolerated. On a secondary endpoint, GLPG1972 dose-dependently reduced mean levels of the cartilage breakdown biomarker ARGS neoepitope by up to 50.4% from baseline to day 29 vs. an increase of 3.6% for placebo. The double-blind, U.S. trial evaluated safety and pharmacokinetics as its primary endpoints.
This year, Galapagos and partner Servier (Suresnes, France) plan to start a global Phase II program of the inhibitor of ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5)...
BCIQ Target Profiles
ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5)